Amid a proxy fight with activist investor Caligan Partners, AMAG Pharmaceuticals implored shareholders to stay the course on the drugmaker’s strategic vision. But with one of its drugs facing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback